NEW YORK – An exploratory analysis within the Phase I TATTON study suggests that circulating tumor DNA (ctDNA) clearance may be a valuable biomarker for evaluating treatment response in patients with EGFR-mutated, MET-amplified non-small cell lung cancer. The findings were presented during the second virtual session of the American Association of Cancer Research's annual meeting.